Progression-Free Survival is a Suboptimal Predictor for Overall Survival Among Metastatic Solid Tumor Clinical Trials

BACKGROUND: The use of overall survival (OS) as the gold standard primary endpoint (PEP) in metastatic oncologic randomized controlled trials (RCTs) has declined in favor of progression-free survival (PFS) without a complete understanding of the degree to which PFS reliably predicts for OS. METHODS:...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Eur J Cancer
Main Authors: Pasalic, Dario, McGinnis, Gwendolyn J., Fuller, C. David, Grossberg, Aaron J., Verma, Vivek, Mainwaring, Walker, Miller, Austin B., Lin, Timothy A., Jethanandani, Amit, Espinoza, Andres F., Diefenhardt, Markus, Das, Prajnan, Subbiah, Vivek, Subbiah, Ishwaria M., Jagsi, Reshma, Garden, Adam S., Fokas, Emmanouil, Rödel, Claus, Thomas, Charles R., Minsky, Bruce D., Ludmir, Ethan B.
Format: Artigo
Jezik:Inglês
Izdano: 2020
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7702022/
https://ncbi.nlm.nih.gov/pubmed/32702645
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2020.06.015
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki